The emotional impact of the intrusiveness of illness and patients' reduced control over several aspects of life were examined in the context of end-stage renal disease. A sample of thirty-five hemodialysis, ten continuous ambulatory peritoneal dialysis (CAPD), and twenty-five posttransplant patients participated in a standardized interview in which a series of eight self-report measures of positive and negative mood, life happiness, self-esteem, depression, and somatic symptoms of distress were obtained. Attending staff also completed a depression rating scale for each participant. Data reduction via principal-components analysis yielded two factors, corresponding to negative and positive mood, and these were submitted to covariance analyses in which age, general nonrenal health, and defensiveness were controlled statistically. Patients' perceptions of increased intrusiveness, and their perception of limited control over eleven life dimensions, each correlated significantly and uniquely with increased negative and decreased positive mood, suggesting that each of these two factors contributes importantly and independently to patients' distress. An "objective" continuum of intrusiveness, constructed by ranking the various treatment modalities represented in the sample, also related significantly to positive (but not to negative) mood levels.

No abstract

One biceps muscle of 8 patients with Duchenne muscular dystrophy was injected at 55 sites with a total of 55 million viable, purified, and contamination-free normal myoblasts (myoblast transfer). The other biceps of each patient was injected with a placebo to serve as a control. The procedure was blinded to the patients, parents, and investigators. Myoblasts derived from a biopsy specimen of the fathers were cultured and purified under strict conditions and carefully screened for microbial contamination. All patients received cyclophosphamide for immunosuppression for 6 or 12 months. No serious complications were observed after myoblast transfer, indicating that the procedure is safe. The overall therapeutic efficiency of myoblast transfer was poor as judged by the results in maximal voluntary force generation, dystrophin content of the muscle, magnetic resonance imaging of the muscle, and the lack of donor-derived DNA and dystrophin messenger RNA in the injected muscle. An improved efficiency of the take of myoblasts might be achieved by using younger cells and injecting the myoblasts with a myonecrotic agent (to increase the prevalence of regeneration) and a basal laminal fenestrating agent.

No abstract

Regression of left ventricular hypertrophy continues beyond the first year after renal transplantation, reaching a nadir at 2 years and persisting into the third and fourth posttransplant years. Failure to regress was associated with older age, hypertension, high pulse pressure in normal-size hearts and low pulse pressure in dilated hearts.